Drug intelligence / Profile preview

HH101785

Development stage: Unknown
Lead developer: Haihe
Modality: Small Molecules
Administration: Oral

Overview

HH101785 is an investigational small molecule drug candidate being developed by Haihe Biopharma for the treatment of advanced solid tumors. While specific details regarding its biological target and mechanism of action are not publicly disclosed in the company's primary pipeline summaries, it is currently positioned in early-phase clinical development. The drug has received Investigational New Drug (IND) approval and is undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and preliminary efficacy in patients with various solid malignancies.

Beyond the preview

Go deeper on HH101785.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH101785.

Explore the full profile